Medical/Pharmaceuticals

EdgeCap-backed Comac Medical Group Expands with Acquisition of ILIFE Consulting, a French Early-phase Specialty CRO

Strategic acquisition marks significant step to establish pan-European footprint and deepens expertise in oncology and early-phase biotech clinical trials. LONDON, May 22, 2025 /PRNewswire/ -- Comac Medical Group ("Group"), based in the UK and backed by EdgeCap Partners, announced today the ac...

2025-05-22 20:20 2581

AXA Study: Over 60% of Hong Kong workers encounter elevated stress levels exceeding global average

Younger generation confronts critical mind health challenges, necessitating enhanced workplace support HONG KONG, May 22, 2025 /PRNewswire/ -- Work-related factors exert a greater influence on the mind health of Hong Kong's workforce compared to the global average, according to the latest finding...

2025-05-22 16:55 4135

€2.6 million innovation challenge launches in Southeast Asia to reimagine support for new parents

LONDON, May 22, 2025 /PRNewswire/ -- Smart, public 'parent pods' located in central community spaces such as markets or parks could soon become a reality around the world as a result of the Good Start Challenge: a €2.6 million global challenge launching today with a call for innovations that impr...

2025-05-22 16:00 3142

PROVISION Study Which Met Its Primary Endpoint Now Demonstrates Similar Clinical Outcomes for FFRangio and FFR

PROVISION Study, Prospective Randomized Trial Evaluating Clinical Outcomes of FFRangio Versus FFR Guidance, Demonstrates Similar MACE Rates at One Year PARIS, May 22, 2025 /PRNewswire/ -- Today at the annual EuroPCR conference taking place in Paris, France, Dr. Toru Tanigaki of Gifu Heart Center...

2025-05-22 15:57 2172

JEC Hosts 5th International Ophthalmology Summit, Launches Groundbreaking Digital Eye Health Platform

* Global eye experts reunite in Jakarta for JECIM 2025, after five-year hiatus * JEC showcases 41 years of ophthalmology leadership and innovation * Launch of Matapedia marks new chapter in eye health education JAKARTA, Indonesia, May 22, 2025 /PRNewswire/ -- JEC Eye Hospitals and Clinics

2025-05-22 14:00 2364

MGI Tech Unveils Next-Generation Automation Portfolio at SLAS Europe 2025 in Germany

HAMBURG, Germany, May 21, 2025 /PRNewswire/ -- MGI Tech Co., Ltd. (MGI), a company dedicated to developing core tools and technologies that drive innovation in life sciences,  is proud to unveil its latest innovation, PrepALL, a flexible liquid handling system, along with the latest version of t...

2025-05-22 10:38 2174

Fourth NDA for Kelun-Biotech's TROP2 ADC sacituzumab tirumotecan (sac-TMT) Accepted by the Center for Drug Evaluation

CHENGDU, China, May 22, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that a new indication application (the "Application") for the Company's trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotec...

2025-05-22 10:09 2785

AnnJi Pharmaceutical Company Announces Positive Phase 1/2a Results for AJ201 in Spinal and Bulbar Muscular Atrophy (SBMA) Patients

TAIPEI, May 22, 2025 /PRNewswire/ -- AnnJi Pharmaceutical Co., Ltd., a clinical-stage Taiwanese biotechnology company focused on addressing unmet medical needs in dermatology, neurology, and rare diseases, today announced positive results from its Phase 1/2a randomized, double-blind, placebo-con...

2025-05-22 09:21 2732

Lethal mutations in pregnancy loss

REYKJAVIK, Iceland, May 21, 2025 /PRNewswire/ -- In a study published in Nature today "Sequence diversity lost in early pregnancy," scientists from deCODE genetics, a subsidiary of Amgen, estimate that around one in 136 pregnancies are lost due to new mutations in the fetus. In other words, milli...

2025-05-21 23:00 3057

Neurophet Participates ASNR 2025: Showcasing Clinical Utility of 'Neurophet AQUA AD'

* Co-CEO Jake Junkil Been joins Industry Collaboration Session to present Neurophet's brain imaging analysis technologies, including Neurophet AQUA AD * Company accelerates partnerships with global pharmaceutical companies and neurology KOLs to drive collaboration in Alzheimer's disease clinic...

2025-05-21 21:00 2961

Kailo Medical Acquires REI AI to Transform the Future of Radiology Reporting

Strategic acquisition brings generative AI into structured workflows, reinforcing Kailo's mission to deliver long-term impact through trusted, collaborative innovation. MELBOURNE, May 21, 2025 /PRNewswire/ -- Kailo Medical, a global leader in structured reporting for medical imaging, today anno...

2025-05-21 20:38 2325

BioDlink Clinches Brazil GMP Audit to Strengthen Emerging Markets Growth

* International recognition of quality system with GMP-compliance in the key markets ofBrazil, Indonesia, Egypt, Colombia and Argentina * Passed its first-ever on-site PIC/S audit, reinforcing its strong commitment to stringent international regulatory standards * Demonstrated BioDlink's cap...

2025-05-21 20:30 2375

SK bioscience Wins Patent Lawsuit Against Pfizer Over Pneumococcal Vaccine

* No patent infringement found in exports of individual conjugate bulk substances and research-use finished products of PCV13 toRussia * Company plans to export PCV13 vaccine components * "We aim for the global PCV market with our 21-valent and next-generation pneumococcal vaccines currently...

2025-05-21 20:00 2944

China's Aphranel MagiCCrystal CaHA Filler Debuts Globally, Ushering in a New Era of Regenerative Aesthetic Medicine

SHANGHAI, May 21, 2025 /PRNewswire/ -- On May 8, 2025, Shanghai Moyom Biotechnology Co., Ltd. unveiled its breakthrough regenerative aesthetic innovation, Aphranel MagiCCrystal CaHA Filler, during an international product debut at The Grand Halls inShanghai, a historic building on the Bund.    ...

2025-05-21 20:00 3506

WHO Foundation and Laerdal Global Health announce US $12.5 million to launch massive Acute Care scale up aiming to save over 50,000 lives per year

Over half of deaths in low-and middle-income countries could be addressed with effective emergency care. GENEVA, May 21, 2025 /PRNewswire/ -- A newly-announced philanthropic partnership between Laerdal Global Health and the WHO Foundation will fund WHO to scale up acute care training for health...

2025-05-21 13:38 3063

Elyon Family Clinic Launches STD Testing Packages Amid Rising Sexual Health Awareness

SINGAPORE, May 21, 2025 /PRNewswire/ -- Elyon Family Clinic & Surgery, an STD clinic in Singapore , has expanded its diagnostic offerings with the launch of two new testing packages: the STI-7 Multiplex Panel and the Genital...

2025-05-21 10:00 1693

Accropeutics Announces Positive Data from Phase 2 Trial of AC-201, an oral, selective TYK2/JAK1 Inhibitor, for the treatment of Moderate-to-Severe Plaque Psoriasis

* Phase 2 primary endpoint of PASI-75 and key secondary endpoints met in all of the three dosing groups at Week 12 * AC-201 was generally well tolerated at all dose levels with no SAEs or AEs leading to discontinuation * Efficacy and safety findings from this Phase 2 trial support advancing ...

2025-05-21 08:50 1843

PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation (IFLI) Announce The First Follicular Lymphoma (FL) Patient Treated with BAFF-R Targeting CAR-T Cells (PMB-CT01) Achieves a Complete Response

* The first heavily pretreated r/r FL patient dosed at City of Hope with PMB-CT01 achieved a CR at one-month post treatment. * A Total of 7/7 r/r B-NHL patients including MCL, DLBCL and FL treated with PMB-CT01 have achieved a sustained CR (1 to 29+ months) with strictly grade 1 CRS and ICAN...

2025-05-20 22:22 2076

Registrational Phase III AMPLIFY trial in biochemical recurrence of prostate cancer commences

SYDNEY, May 20, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that it has commenced ...

2025-05-20 21:02 2427

Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-022 (CLDN18.2 ADC) In Combination with KEYTRUDA® (pembrolizumab)

- ATG-022 is Antengene's CLDN18.2 antibody-drug conjugate; KEYTRUDA® (pembrolizumab) is MSD's anti-PD-1 therapy. SHANGHAI and HONG KONG, May 20, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical compa...

2025-05-20 20:00 2436
1 ... 112113114115116117118 ... 646